Key takeaways
- Company stage changes everything: founders decide at startups, global procurement at large pharma.
- Quality assurance signs off anything used in regulated work.
- Funding rounds, trial phase changes and new sites create buying windows.
- Scientific accuracy matters: get the company's science right before you write.
Who are the life sciences decision makers
Life sciences decisions are shared between the scientists who use a product, the people who run the labs and the teams who approve suppliers. The R&D director or head of research sets scientific priorities, the lab operations head runs equipment, space and services, and quality assurance decides whether anything can be used in regulated work.
- Chief scientific officer or R&D director: research priorities and budget
- Head of lab operations or lab manager: equipment, consumables and services
- Head of quality or QA manager: validation and supplier approval
- Clinical operations lead: trial delivery and outsourced partners
- Procurement or strategic sourcing: preferred suppliers at larger companies
How does company stage change biotech sales prospecting
Company stage changes who decides and how fast. At an early research-stage biotech, a small leadership team decides quickly, with spending tied closely to the last funding round, so timing after a raise matters.
Clinical-stage companies outsource much of their work to research and manufacturing partners, so clinical operations and outsourcing leads become central. Large pharma buys through global procurement, preferred supplier lists and long qualification cycles, where a site-level champion helps but cannot decide alone.
Which triggers make biotech companies buy
Biotech companies buy when their science moves to a new stage or their footprint grows. A funding round, a programme entering a new trial phase, a partnership with a larger company or a new lab or manufacturing site all create needs with deadlines.
Hiring for lab operations, quality or clinical roles shows where the pressure is. Public pipeline pages, press releases and trial registries tell you what each company is working on and how far along it is.
Why do GxP and validation shape selling to biotech companies
GxP shapes the sale because regulated work must follow good practice guidelines for manufacturing, laboratories and clinical trials, and in the UK the MHRA regulates medicines. Equipment and software used in those processes must be validated, documented and controlled for change, which brings quality assurance into the decision.
Early discovery work is usually lighter, so it can be a faster entry point. If your product will be used in regulated work, offer the validation documentation buyers expect and confirm the requirements with your adviser.
What should a research brief cover before outreach
A research brief should cover the company's stage, therapy areas, modality, sites, partners and recent news. Getting the science wrong, such as describing a gene therapy company as a small molecule developer, ends the conversation before it starts.
How to find and approach life sciences leads
Research comes first in this industry, because buyers notice when it has not been done.
- Choose the stage and type of company your product suits, from research-stage biotech to large pharma.
- List companies by therapy area, modality and site location.
- Write a short research brief on each, covering pipeline stage, recent funding and partners.
- Name the R&D, lab operations, quality and procurement leads relevant to your product.
- Prepare validation documentation if your product will touch regulated work.
- Open with the company's own milestone and the problem it creates for the team.
Where Pebbles Ai fits
- CapabilityResearch & analysisAsk an assistant to read a company's pipeline page and press releases and build a research brief, with numbered citations and a source list to check before you decide.
- CapabilityProspecting & customer recordsFind fresh leads takes up to ten named companies, roles such as head of lab operations or QA manager and a site location, and returns people from Pebbles Ai's own growing B2B contact database, GDPR compliant.
- FoundationAgent memoryAgent memory carries short facts you share about a project, such as the therapy areas you are targeting, into later chats, so drafts start from what you already know.
Common questions
Who should I contact first at a biotech startup?
Usually the chief scientific officer or the head of lab operations, depending on what your product does. At very small companies the chief executive may decide.
How long do pharma sales cycles take?
Often longer than in most industries, because supplier qualification and validation take time. Plan for several stages and several approvers.
Where can I see what a biotech company is working on?
Its own pipeline page and press releases, public trial registries and its funding announcements are the usual starting points.
About this page. Written by the Pebbles Ai team for people who run sales, marketing and growth. Last updated .
